Depomed Inc

Depomed — Investor Presentation (February 2018)

19 slides from Depomed's investor presentation, Feb 14, 2018

  1. Slide 1: Forward Looking Statements

    Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning established by the Private Securities Litigation Reform Act of 1995 ("Act"). The forward-looking statements are intended to qualify under provisions of the federal securities laws for "safe harbor"

  2. Slide 2: Principles Guiding the Way We Do Business

    Principles Guiding the Way We Do Business PUTTING the Patient First PRODUCTIVITY Aimed at Improving Effectiveness Across the Business PROFITABILITY in Line with Our Peer Group 3 February 2018

  3. Slide 3: A Clear Strategy for Growth

    A Clear Strategy for Growth Executing on a Three Pillar Growth Strategy 4 MAINTAIN a Strong/Profitable NUCYNTA Franchise GROW Neurology and Pain Businesses BUILD a New Specialty Business Collegium Transaction December 2017 90 Rep Salesforce Operational October 2017 Cosyntropin Depot Transaction Anno

  4. Slide 4: Collegium Deal Supports Maintaining a Strong/Profitable NUCYNTA Franchise

    Collegium Deal Supports Maintaining a Strong/Profitable NUCYNTA® Franchise 5 MAINTAIN With the January closing, Collegium Pharmaceutical obtained the rights to commercialize NUCYNTA® Depomed retains ownership of the NDAs and be responsible for NUCYNTA® product supply Depomed maintains responsibility

  5. Slide 5: Industrial Logic is Clear and Compelling: Financially, Strategically and Patient-Focused

    Industrial Logic is Clear and Compelling: Financially, Strategically and Patient-Focused Depomed Collegium Financially Immediately Accretive Improves Absolute EBIDTA Strategically Collegium as a Leader in Pain and Depomed Ability to Focus on Neurology/ Orphan Drugs Allows Significant Cost Synergies

  6. Slide 6: Collegium: Ideal Partner to Take NUCYNTA to the Next Level

    Collegium: Ideal Partner to Take NUCYNTA® to the Next Level Recognized as an emerging leader in pain management and committed to building a leading pain company Xtampza® ER is the fastest growing Extended Release branded opioid Strong home office, commercial and managed care infrastructures Salesfor

  7. Slide 7: Depomed $135 Million Annual Payment - Highly Secure and Independent of Collegium's Financial Position

    Depomed $135 Million Annual Payment - Highly Secure and Independent of Collegium’s Financial Position 8 100% 100% Gross Sales go into lock box Includes a $33.75M letter of credit should Collegium fall below the minimum Special Purpose Vehicle (SPV) Bankruptcy Protected 35% Daily sweep of Gross Sales

  8. Slide 8: Potential for EBIDTA Improvement

    Potential for EBIDTA Improvement Assumed NUCYNTA Net Sales* 9 $220mm $240mm $260mm Potential EBIDTA Enhancement Resulting from Collegium Transaction $50 $37 $24 Royalty Payment Change to Grünenthal ($3.2) - $1.2 Net EBIDTA Improvement $46.8 $37 $25.2 Guidance to be Provided in 2018 *For illustrative

  9. Slide 9: Grow Our Neurology and Pain Businesses

    GROW Grow Our Neurology and Pain Businesses September marked the completed relaunch of our Neurology salesforce with 90 representatives Provides proper support to highly-promotionally sensitive products Gralise® and CAMBIA ® Creates credible platform to expand with new products Committed to adding a

  10. Slide 10: Build A New Specialty Business

    Build A New Specialty Business Establishment of a New Specialty Products Business Unit Mark Booth as General Manager brings 30+ years of biopharma experience Objective is to build a portfolio of specialty/orphan drugs addressing the unmet needs of the patient, physician and payors Provides a platfor

  11. Slide 11: Transformational Transaction Creates New Specialty Business

    Transformational Transaction Creates New Specialty Business Depomed/ Slán Medicinal Holdings Limited Acquisition of Cosyntropin (Synthetic ACTH Depo) provides a late-stage, high-value product Depomed is the exclusive licensee for United States Current U.S. market is led by H.P. Acthar® Gel (Natural

  12. Slide 12: Headquarters Restructuring and Relocation Aligns with New Business Model

    Headquarters Restructuring and Relocation Aligns with New Business Model Headquarters Relocation in 2018: Evaluating Mid-West and East Coast Sites Provides Improved Access to Pharmaceutical Talent Current Footprint: 60,000 square feet housing 120 employees 380 person salesforce New Footprint: Approx

  13. Slide 13: Gralise: Differentiated within the 71MM Annual Prescription Market

    Gralise®: Differentiated within the 71MM Annual Prescription Highly Promotionally Sensitive Market Indication Management of post-herpetic neuralgia Performance 2016 net sales of $88 million 3Q 2017 net sales of $21 million Clinical Differentiation Only once-daily formulation of gabapentin Significan

  14. Slide 14: Cambia: Differentiated within the 15MM Annual Prescription Market

    Cambia®: Differentiated within the 15MM Annual Prescription Highly Promotionally Sensitive Market Indication Performance Clinical Differentiation Acute migraine attacks in adults 2016 net sales of $31 million 3Q 2017 net sales of $8 million Only single-agent in therapeutic class for acute migraine R

  15. Slide 15: Zipsor: Differentiated within the 11MM Annual Prescription Market

    Zipsor®: Differentiated within the 11MM Annual Prescription Highly Promotionally Sensitive Market Indication Mild to moderate acute pain in adults Performance 2016 net sales of $28 million 3Q 2017 net sales of $3.2 million Clinical Differentiation Only prescription NSAID in gel cap form Unique ProSo

  16. Slide 16: Milestones Driving Growth in 2018 and Beyond

    NUCYNTA® Commercialization Agreement: Close Agreement with Collegium Pharmaceutical Synthetic Cosyntropin (Synthetic ACTH Depot): Commenced Investigational New Drug (IND) Trial in Infantile Spasms Purdue Litigation: Pre-Trial Conference to Set Trial Date Milestones Driving Growth in 2018 and Beyond

  17. Slide 17: Depomed's Transformation is Well Underway

    180 Days Ago NUCYNTA and Lazanda franchises placed Depomed with a heavy opioid concentration in a volatile market NUCYNTA field force needed to be downsized and retargeted with significant dislocation risk Promotionally-sensitive neurology products under resourced with ~ 40 person field force No Thi

  18. Slide 18: Our Commitment to Shareholders

    Our Commitment to Shareholders 19 Execute on a Clear Strategy of Maintain a Strong NUCYNTA Franchise, Grow Our Neurology and Pain Businesses and Build a New Specialty Business Leverage Opportunities to Drive Superior Profitability Committed to Putting the Patient First February 2018

  19. Slide 19: Execute on a Clear Strategy

    Execute on/a Clear Strategy of Maintain a Strong NUCYNTA Franchise, Committed to Grow OuPNeurology and Pain Businesses and Build a New Specialty Business Putting the Patient First Seoeromen

Depomed — Investor Presentation (February 2018) on 6ix